GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC

GlaxoSmithKline PLC logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $41.13
  • 50 Day Moving Average: $42.87
  • 200 Day Moving Average: $42.96
  • 52-Week Range: $2,430,500,000.00 - $37.82
  • Trailing P/E Ratio: 2570.62
  • Foreward P/E Ratio: 15.40
  • P/E Growth: 1.67
  • Market Cap: $99.97B
  • Outstanding Shares: 2,430,500,000
  • Beta: 0.89
  • Net Margins: 0.21%
  • Return on Equity: 56.57%
  • Return on Assets: 7.57%
  • Debt-to-Equity Ratio: 3.57%
  • Current Ratio: 0.93%
  • Quick Ratio: 0.63%
Additional Links:
Companies Related to GlaxoSmithKline PLC:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (?)
Ratings Breakdown: 2 Sell Ratings, 8 Hold Ratings, 11 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $48.25 (17.31% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
DateFirmActionRatingPrice TargetDetails
10/20/2016InvestecInitiated CoverageBuyView Rating Details
10/19/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details
9/23/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
9/23/2016Piper Jaffray Cos.Initiated CoverageOverweightView Rating Details
9/20/2016Bank of America Corp.Reiterated RatingBuy$50.00View Rating Details
9/16/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details
9/14/2016Jefferies GroupReiterated RatingBuyView Rating Details
9/13/2016BNP ParibasDowngradeNeutral -> UnderperformView Rating Details
9/12/2016HSBCReiterated RatingBuyView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00View Rating Details
7/28/2016Goldman Sachs Group Inc.Reiterated RatingBuyView Rating Details
6/27/2016Deutsche Bank AGReiterated RatingHoldView Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00View Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00View Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellView Rating Details
10/20/2015Credit Suisse Group AGUpgradeUnderperform -> NeutralView Rating Details
6/26/2015Liberum CapitalUpgradeSell -> HoldView Rating Details
5/22/2015Berenberg BankReiterated RatingHoldView Rating Details
4/16/2015Barclays PLCReiterated RatingOverweightView Rating Details
3/30/2015Kepler Capital MarketsReiterated RatingHoldView Rating Details
2/6/2015Panmure GordonReiterated RatingHoldView Rating Details
2/5/2015S&P Equity ResearchDowngradeHoldView Rating Details
1/22/2015New Street ResearchDowngradeReduceView Rating Details
(Data available from 10/23/2014 forward)


Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/3/2016Q415$0.18$0.18$6.28 billion$6.29 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53ViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48ViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90ViewListenView Earnings Details
7/23/2014Q114$0.71$0.65ViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70ViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
Current Year EPS Consensus Estimate: $2.53 EPS
Next Year EPS Consensus Estimate: $2.67 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.50$0.50$0.50
Q2 20162$0.54$0.55$0.55
Q3 20162$0.72$0.78$0.75
Q4 20161$0.64$0.64$0.64
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Annual Dividend:$1.85
Dividend Yield:4.50%
Dividend Growth:2.50% (3 Year Average)
Payout Ratio:6,166.67% (Based on Trailing 12 Months of Earnings)
73.12% (Based on Current Year Consensus EPS Estimate)
69.29% (Based on Next Year Consensus EPS Estimate)

Dividend History for GlaxoSmithKline PLC (NYSE:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline PLC (NYSE:GSK)
No insider trades for this company have been tracked by


Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
DateHeadline logoGlaxoSmithKline plc : quaterly earnings release (NYSE:GSK) - October 21 at 5:25 PM
News IconRating Action: What To Expect From GlaxoSmithKline PLC (ADR) (NYSE:GSK) After Investec Capital’s New Coverage (NYSE:GSK) - October 21 at 5:25 PM logoWhat’s to Be Expected from Novartis’s 3Q16 Earnings? (NYSE:GSK) - October 21 at 5:25 PM
News IconGlaxoSmithKline plc (GSK) Earns “Buy” Rating from Bryan, Garnier & Co - DailyQuint (NYSE:GSK) - October 21 at 8:28 AM
News IconStock in the Trader's Focus- GlaxoSmithKline plc's (GSK) - Hot Stocks Point (NYSE:GSK) - October 21 at 8:28 AM
News IconHanson & Doremus Investment Management Reached $1162000 position of GlaxoSmithKline PLC (GSK) - DailyQuint (NYSE:GSK) - October 21 at 8:28 AM logoBetter Buy: Pfizer Inc. vs. GlaxoSmithKline plc - Motley Fool (NYSE:GSK) - October 21 at 8:28 AM logoBetter Buy: Pfizer Inc. vs. GlaxoSmithKline plc -- The Motley Fool - Motley Fool (NYSE:GSK) - October 21 at 8:28 AM logoWhich is the better buy? GlaxoSmithKline plc vs Shire plc (NYSE:GSK) - October 21 at 8:28 AM logoWhy Despite Alkermes Success, Suicidal Ideation Still Eludes Big Pharma (NYSE:GSK) - October 21 at 8:28 AM
News IconBetter Buy: Pfizer Inc. vs. GlaxoSmithKline plc | Markets & Stocks ... - Bloomington Pantagraph (NYSE:GSK) - October 20 at 5:23 PM
News IconBetter Buy: Pfizer Inc. vs. GlaxoSmithKline plc - Fox Business (NYSE:GSK) - October 20 at 5:23 PM
News IconGlaxoSmithKline plc (GSK) Rating Reiterated by Bryan, Garnier ... - DailyQuint (NYSE:GSK) - October 20 at 10:48 AM
News IconTop Gainers of the Day: GlaxoSmithKline plc (NYSE:GSK) from Drug Manufacturers – Major (NYSE:GSK) - October 19 at 5:41 PM logoGlaxoSmithKline Plc (GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App (NYSE:GSK) - October 19 at 10:13 AM
News IconDeutsche Bank AG Reaffirms Hold Rating for GlaxoSmithKline plc (GSK) - DailyQuint (NYSE:GSK) - October 18 at 5:15 PM
News IconTealwood Asset Management Inc. cuts position of GlaxoSmithKline PLC (GSK) - DailyQuint (NYSE:GSK) - October 18 at 5:15 PM logoGlaxoSmithKline Plc (NYSE:GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App - Market Exclusive (NYSE:GSK) - October 18 at 10:20 AM
News IconGlaxoSmithKline plc (GSK) PT Raised to GBX 1950 at Jefferies Group - DailyQuint (NYSE:GSK) - October 18 at 10:20 AM logoGSK January 2019 Options Begin Trading (NYSE:GSK) - October 17 at 5:18 PM logoStocks in Queue ConocoPhillips (NYSE:COP), GlaxoSmithKline plc (ADR) (NYSE:GSK) - Wall Street 24 (NYSE:GSK) - October 15 at 10:06 AM logoGSK Wants Fraud Claims Dismissed In Zofran MDL (NYSE:GSK) - October 14 at 5:13 PM
News IconStock Value Diminishing Pre-Market for GlaxoSmithKline plc (NYSE:GSK) - CSZ News (NYSE:GSK) - October 14 at 5:13 PM
News IconAnalysts Take the Wheel on GlaxoSmithKline PLC (NYSE:GSK) Shares and Where They Might Be Headed - CSZ News (NYSE:GSK) - October 14 at 5:13 PM
News IconGlaxoSmithKline plc's (GSK): Traders Watch List - Hot Stocks Point (NYSE:GSK) - October 14 at 5:13 PM
News IconStock Momentum Curbed Pre-Bell, Gapping Down: GlaxoSmithKline plc (NYSE:GSK) - CSZ News (NYSE:GSK) - October 13 at 5:22 PM
News IconBargain-Counter Stock or Pricey? Update on GlaxoSmithKline plc (NYSE:GSK) - CSZ News (NYSE:GSK) - October 13 at 5:22 PM
News IconGlaxoSmithKline PLC (NYSE:GSK) Quarterly Sales Review - The Newburgh Press (NYSE:GSK) - October 13 at 5:22 PM logoBofA: Expect upside to Merck estimates (NYSE:GSK) - October 13 at 5:22 PM logoShark Tank's O'Leary Bullish on GlaxoSmithKline (GSK) (NYSE:GSK) - October 13 at 5:22 PM logoGlaxoSmithKline : *JEFFERIES RAISES GLAXOSMITHKLINE PRICE TARGET TO 1950 PENCE - 'BUY' (NYSE:GSK) - October 13 at 8:30 AM logoDefensive stocks showdown: GlaxoSmithKline plc vs Reckitt Benckiser Group plc (NYSE:GSK) - October 13 at 8:30 AM logoThe Zacks Analyst Blog Highlights: Chevron, Cisco Systems, GlaxoSmithKline, NIKE and BP (NYSE:GSK) - October 12 at 10:21 AM
News IconLarge Cap Drug Manufacturers – Major: GlaxoSmithKline plc (NYSE:GSK) (NYSE:GSK) - October 11 at 5:31 PM logoWhy Doctors Without Borders is turning down a million free pneumonia vaccines from Pfizer (NYSE:GSK) - October 11 at 5:31 PM logoWhich Big Pharma Is the Best Dividend Stock? (NYSE:GSK) - October 10 at 5:02 PM
News IconGlaxoSmithKline plc's (GSK): Stock in the Traders Limelight - Hot Stocks Point (NYSE:GSK) - October 10 at 9:58 AM
News IconCurrent Price Targets For GlaxoSmithKline PLC (NYSE:GSK ... - NewsDen (NYSE:GSK) - October 8 at 9:55 AM logoGSK has been a Brexit winner, but can the FTSE share go higher? (NYSE:GSK) - October 6 at 5:13 PM
News IconGlaxoSmithKline plc's (GSK): Stock Alert - Hot Stocks Point (NYSE:GSK) - October 5 at 10:30 AM logoGilead Sciences: More Competition?!?! (NYSE:GSK) - October 5 at 10:30 AM logoHow Much Return Could Gilead Offer in the Next Year? (NYSE:GSK) - October 5 at 10:30 AM logoGlaxoSmithKline Plc (NYSE:GSK) Settles China Bribery Charges With $20M - Market Exclusive (NYSE:GSK) - October 4 at 5:10 PM
News IconStock in the Traders Limelight- GlaxoSmithKline PLC (NYSE:GSK) - Hot Stocks Point (NYSE:GSK) - October 4 at 10:07 AM
News IconGlaxoSmithKline to Pay $20M SEC Fine for Bribes in China (NYSE:GSK) - October 3 at 5:05 PM logoNovartis Is Surviving (NYSE:GSK) - October 3 at 5:05 PM logoGlaxoSmithKline To Pay USD20 Million To Settle US China Bribery Case (NYSE:GSK) - October 3 at 9:57 AM
News IconGlaxoSmithKline plc (NYSE:GSK) from Drug Manufacturers – Major – Todays Top Gains (NYSE:GSK) - October 3 at 9:57 AM logo2 FTSE stocks I’m tipping to take off in October! (NYSE:GSK) - October 3 at 9:57 AM logoStrong Revenue Points to Gains at GlaxoSmithKline (NYSE:GSK) - October 2 at 9:43 AM


GlaxoSmithKline PLC (NYSE:GSK) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff